NCT05442463

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Hormone Therapy and Angiotensin-Dependent Arterial and Renal

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: University of Calgary · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women. 2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.

Detailed description

Participants are screened for eligibility. Study involves a 4.5 hour morning in the lab: 1. Participants come fasting 2. IV infusion and blood draws 3. Non invasive testing - Holter monitor, sphygmocor, bioelectrical impedance, blood pressure checks

Conditions

• Hormone Therapy

Interventions

Type	Name	Description
DRUG	Captopril Tablets	Captorpril challenge to each participant
DRUG	Iohexol	Iohexol infusion to evaluate measured GFR

Timeline

• Start date: 2020-11-30
• Primary completion: 2025-11-30
• Completion: 2025-11-30
• First posted: 2022-07-05
• Last updated: 2025-03-27

Locations

1 site across 1 country: Canada